SRD5A2 and benign prostatic hyperplasia: Finasteride, which specifically inhibits SRD5A2 to inhibit AR activity, results significantly in the inhibition of the expression of testosterone-induced AR-associated genes in BPH-1 cells, reducing the mRNA levels of SRD5A2, AR, and PSA (Figure 2B).